Not all GLP-1 medications are the same, and not all are approved for adolescents. Currently, two GLP-1 receptor agonists have received FDA approval for chronic weight management in adolescents aged 12 and older, Wegovy® and Saxenda®. A third, Zepbound®, is expected to receive adolescent approval soon. Here's what parents should know about each option.
Thryvwell prescribes only FDA-approved GLP-1 medications (Wegovy® and Saxenda®). We never use compounded semaglutide or tirzepatide.
FDA-approved options
Wegovy® (semaglutide)
Saxenda® (liraglutide)
Zepbound® (tirzepatide)
A note on compounded medications
You may have seen advertisements for "compounded semaglutide" or "generic GLP-1" at lower prices. These are not FDA-approved, have not been tested in adolescent clinical trials, and lack the quality controls of brand-name medications.
Thryvwell exclusively prescribes FDA-approved medications with established safety profiles in adolescent populations. When it comes to developing bodies, clinical evidence matters more than cost savings.
Wondering if this applies to your child? The 2-minute eligibility check tells you if Thryvwell could be a fit. No commitment, no payment info.
How your child's physician chooses
The medication selection is individualized based on:
This isn't a one-size-fits-all decision. Your child's physician will discuss the options and recommend the best fit during the clinical intake.
Sources
- FDA. Wegovy® Prescribing Information (2022)
- FDA. Saxenda® Prescribing Information: Pediatric Indication (2020)
- Eli Lilly. Zepbound® SURMOUNT-Jr Trial Results (adolescent approval pending)
- Weghuber, D. et al. NEJM (2022); Kelly, A.S. et al. NEJM (2020)
Find out which option is right for your child
Our physicians will recommend the best medication based on your child's individual needs
The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.
